View Item 

Show simple item record

Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
dc.contributor.authorGimeno, Juan R.
dc.contributor.authorOlivotto, Iacopo
dc.contributor.authorRodríguez, Ana Isabel
dc.contributor.authorHo, Carolyn Y.
dc.contributor.authorFernández, Adrián
dc.contributor.authorQuiroga, Alejandro
dc.contributor.authorEspinosa, Mari Angeles
dc.contributor.authorGómez-González, Cristina
dc.contributor.authorRobledo, María
dc.contributor.authorTojal-Sierra, Lucas
dc.contributor.authorDay, Sharlene M.
dc.contributor.authorOwens, Anjali
dc.contributor.authorBarriales-Villa, Roberto
dc.contributor.authorLarrañaga, Jose María
dc.contributor.authorRodríguez-Palomares, Jose
dc.contributor.authorGonzález-del-Hoyo, Maribel
dc.contributor.authorPiqueras-Flores, Jesús
dc.contributor.authorReza, Nosheen
dc.contributor.authorChumakova, Olga
dc.contributor.authorAshley, Euan A.
dc.contributor.authorParikh, Victoria
dc.contributor.authorWheeler, Matthew
dc.contributor.authorJacoby, Daniel
dc.contributor.authorPereira, Alexandre C.
dc.contributor.authorSaberi, Sara
dc.contributor.authorHelms, Adam S.
dc.contributor.authorVillacorta, Eduardo
dc.contributor.authorGallego-Delgado, María
dc.contributor.authorCastro, Daniel
dc.contributor.authorDomínguez, Fernando
dc.contributor.authorRipoll-Vera, Tomás
dc.contributor.authorZorio-Grima, Esther
dc.contributor.authorSánchez-Martínez, José Carlos
dc.contributor.authorGarcía-Álvarez, Ana
dc.contributor.authorArbelo, Elena
dc.contributor.authorMogollón, María Victoria
dc.contributor.authorFuentes-Cañamero, María Eugenia
dc.contributor.authorGrande, Elias
dc.contributor.authorPeña, Carlos
dc.contributor.authorMonserrat, Lorenzo
dc.contributor.authorLakdawala, Neal K.
dc.contributor.authorMuñoz-Esparza, Carmen
dc.date.accessioned2022-08-02T18:56:13Z
dc.date.available2023-09-02 14:56:12en
dc.date.available2022-08-02T18:56:13Z
dc.date.issued2022-08
dc.identifier.citationGimeno, Juan R.; Olivotto, Iacopo; Rodríguez, Ana Isabel ; Ho, Carolyn Y.; Fernández, Adrián ; Quiroga, Alejandro; Espinosa, Mari Angeles; Gómez-González, Cristina ; Robledo, María ; Tojal-Sierra, Lucas ; Day, Sharlene M.; Owens, Anjali; Barriales-Villa, Roberto ; Larrañaga, Jose María ; Rodríguez-Palomares, Jose ; González-del-Hoyo, Maribel ; Piqueras-Flores, Jesús ; Reza, Nosheen; Chumakova, Olga; Ashley, Euan A.; Parikh, Victoria; Wheeler, Matthew; Jacoby, Daniel; Pereira, Alexandre C.; Saberi, Sara; Helms, Adam S.; Villacorta, Eduardo; Gallego-Delgado, María ; Castro, Daniel; Domínguez, Fernando ; Ripoll-Vera, Tomás ; Zorio-Grima, Esther ; Sánchez-Martínez, José Carlos ; García-Álvarez, Ana ; Arbelo, Elena; Mogollón, María Victoria ; Fuentes-Cañamero, María Eugenia ; Grande, Elias; Peña, Carlos ; Monserrat, Lorenzo; Lakdawala, Neal K.; Muñoz-Esparza, Carmen (2022). "Impact of SARS- Cov- 2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry." ESC Heart Failure 9(4): 2189-2198.
dc.identifier.issn2055-5822
dc.identifier.issn2055-5822
dc.identifier.urihttps://hdl.handle.net/2027.42/173082
dc.description.abstractAimsTo describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events.Methods and resultsThree hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600).ConclusionsOver one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherSARS-CoV-2 infection
dc.subject.otherRegistry
dc.subject.otherPrognosis
dc.subject.otherHypertrophic cardiomyopathy
dc.subject.otherCOVID-19
dc.subject.otherHeart failure
dc.titleImpact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173082/1/ehf213964_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173082/2/ehf213964.pdf
dc.identifier.doi10.1002/ehf2.13964
dc.identifier.sourceESC Heart Failure
dc.identifier.citedreferenceDy LF, Lintao RCV, Cordero CP, Cabaluna ITG, Dans LF. Prevalence and prognostic associations of cardiac abnormalities among hospitalized patients with COVID-19: A systematic review and meta-analysis. Sci Rep. 2021; 11: 8449.
dc.identifier.citedreferenceGiustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vicenzi M, Danilov T, Kukar N, Shaban N, Kini A, Camaj A, Bienstock SW, Rashed ER, Rahman K, Oates CP, Buckley S, Elbaum LS, Arkonac D, Fiter R, Singh R, Li E, Razuk V, Robinson SE, Miller M, Bier B, Donghi V, Pisaniello M, Mantovani R, Pinto G, Rota I, Baggio S, Chiarito M, Fazzari F, Cusmano I, Curzi M, Ro R, Malick W, Kamran M, Kohli-Seth R, Bassily-Marcus AM, Neibart E, Serrao G, Perk G, Mancini D, Reddy VY, Pinney SP, Dangas G, Blasi F, Sharma SK, Mehran R, Condorelli G, Stone GW, Fuster V, Lerakis S, Goldman ME. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020; 76: 2043 – 2055.
dc.identifier.citedreferenceElliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29: 270 – 276.
dc.identifier.citedreferencePeckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, Rosser EC, Webb K, Deakin CT. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020; 11: 6317.
dc.identifier.citedreferenceMaron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart Association, Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006; 113: 1807 – 1816.
dc.identifier.citedreferenceHo CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018; 138: 1387 – 1398.
dc.identifier.citedreferenceCharron P, Elliott PM, Gimeno JR, Caforio ALP, Kaski JP, Tavazzi L, Tendera M, Maupain C, Laroche C, Rubis P, Jurcut R, Calò L, Heliö TM, Sinagra G, Zdravkovic M, Kavoliuniene A, Felix SB, Grzybowski J, Losi MA, Asselbergs FW, García-Pinilla JM, Salazar-Mendiguchia J, Mizia-Stec K, Maggioni AP, EORP Cardiomyopathy Registry Investigators. The cardiomyopathy registry of the EURObservational research programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018; 39: 1784 – 1793.
dc.identifier.citedreferenceSubdirección General de Tecnologías de la Información (SGTI) of the Servicio Murciano de Salud. Covid-19 disease in the Region of Murcia. Epidemiologic reports. Accessed 2 February 2021. https://www.murciasalud.es/pagina.php?id=458869
dc.identifier.citedreferenceThaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, Elliott PM, McKenna WJ. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005; 91: 920 – 925.
dc.identifier.citedreferenceChung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res. 2021; 128: 1214 – 1236.
dc.identifier.citedreferenceGuo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5: 811 – 818.
dc.identifier.citedreferenceGuan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708 – 1720.
dc.identifier.citedreferenceGuan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55: 2000547.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ehf213964_am.pdf
Size:
1.127MB
Format:
PDF
View/Open
Name:
ehf213964.pdf
Size:
1.571MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.